RBR-5v3k5d招募中3 期
Clinical, Open label, Phase III, Multicenter, Prospective, Comparative, Controlled, Randomized Study to Assess the Effectiveness of Systemic Oxygen Therapy with Medicinal Ozone in Early Control of Disease Progression in Patients with COVID-19 who have Acute Infectious Respiratory Symptoms
Sociedade Brasileira de ozonioterapia médica0 个研究点开始时间: 2020年10月2日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 18Y 至 90Y（—）
入选标准
- •The inclusion criteria for this study are; Patients with acute infectious respiratory symptoms evaluated in hospital or outpatient settings, based on the flow chart suggested by Hospital Israelita Albert Einstein (19.03.2020); Laboratory diagnosis confirmed for Covid-19 (RT-PCR of nasal and / or oropharyngeal secretion) ; Both sexes; Age greater than or equal to 18 years; Signed free and informed consent form; Availability to follow the research protocol
排除标准
- •G6PD enzyme deficiency (activity below 60% according to Yoshida classification 242; Pregnancy; Women in lactation Clinically decompensated hyperthyroidism; Severe decompensated arterial hypertension; Severe active or recent bleeding from severe Anemia (Hemoglobin less than 6 g / dL); severe unstable cardiovascular disease ; Participation in another clinical study for less than 30 days; Impossibility of adhering to the research protocol; Any important clinical condition that, in the Investigator's opinion, may bring risks to the patient and prevent him from proceeding safely; Suspected or recent pregnancy as a precaution due to ethical issues, since there are studies of genotoxicity in experimental animals proving the safety of Ozone Therapy in the sense of the absence of genetic changes induced by Medicinal Ozone; any important clinical condition that in the Researcher's opinion may bring risks to the patient and prevent that the research protocol proceeds with safety
研究者
相似试验
进行中（未招募）
1 期
Clinical trial to evaluate a new combination of drugs (Filanesib + pomalidomide + dexamethasone) for the treatment of relapsed or refractory (drug-resistant) multiple myeloma.Patients with Multiple Myeloma in relapsed or refractoryMedDRA version: 17.1Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2014-002740-41-ESFundación Pethema24
招募中
3 期
Phase III, multicentre, randomized, open clinical trial comparing treatment with allogenic mesenchymal cells against autologous mesenchymal cells and against active control with hyaluronic acid in patients with knee osteoarthritis.Knee osteoarthritis2024-514545-11-00Fundacion Instituto De Estudios De Ciencias De La Salud De Castilla Y Leon120
已完成
3 期
Open-label clinical trial of Enoxaparin (low molecular weight heparin) given concomitantly with chemotherapy vs chemotherapy alone in patients with inoperable gastric and gastro-oesophageal cancer.CTRI/2009/091/000885Thrombosis Research Institute740
进行中（未招募）
1 期
Phase III,multicentre,open-label,prospective randomised trial comparing Imatinib alone at 400mg versus 800mg daily versus Imatinib 400mg daily plus PEG Interferon-alpha with newly diagnosed chronic myeloid leukaemia - SpiritChronic Myeloid Leukaemia (Chronic Phase)EUCTR2004-001622-24-IEewcastle Hospital Trust259
进行中（未招募）
3 期
Clinical trial/study for lung cancer patients with ROS1 positiveCTRI/2022/04/041861F HoffmannLa Roche Ltd